The fluctuations of the market, so often driven by sentiment rather than substance, offered a particularly diverting spectacle on Tuesday. Edgewise Therapeutics (EWTX +2.18%), a company daring enough to pursue genuine innovation, found itself momentarily favored by the capricious gods of Wall Street. It rose, one might say, with a grace that rather outshone the pedestrian advance of the S&P 500 index (a mere 0.3% increase, how terribly predictable).
A Modest Reappraisal
The catalyst, as is so often the case, was a pronouncement from the oracle – in this instance, Tessa Romero of JPMorgan Chase. She elected to elevate her price target for Edgewise from $34 to $45. A most agreeable increase, though one wonders if such valuations aren’t merely exercises in optimistic arithmetic. Still, maintaining a ‘buy’ recommendation is a gesture of confidence, or perhaps, a shrewd anticipation of the herd.
Ms. Romero appears to believe that Edgewise possesses several programs with the potential to… well, to actually succeed. A novel concept in this industry. Renewed attention is focused on EDG-7500, a promising candidate for treating hypertrophic cardiomyopathy. One suspects the heart, that most poetic of organs, is a particularly appealing target for investors – though they rarely seem to possess one themselves.
Last week, Edgewise unveiled long-term data from a study of sevasemten, a treatment for Becker muscular dystrophy. The results indicated stabilization of function in patients. A remarkable achievement, and one that demonstrates, contrary to the grim expectations of natural history, that progress is, indeed, possible. It is, after all, far more amusing to defy expectations than to fulfill them.
A Double Helping of Promise
It is impressive enough when a biotechnology firm possesses a single promising candidate in late-stage development. Edgewise, however, has two. And, as if to further indulge the discerning investor, it is also cultivating another two within the cardiovascular sphere. This, my dear reader, is what separates the truly interesting companies from the merely… plentiful. To have ambition is one thing; to possess the means to realize it is quite another.
One is tempted to observe that in a world obsessed with instant gratification, a company focused on genuine, long-term innovation is something of an anomaly. But then, isn’t it always the anomalies that prove most captivating?
Read More
- Spotting the Loops in Autonomous Systems
- Seeing Through the Lies: A New Approach to Detecting Image Forgeries
- Staying Ahead of the Fakes: A New Approach to Detecting AI-Generated Images
- Julia Roberts, 58, Turns Heads With Sexy Plunging Dress at the Golden Globes
- Palantir and Tesla: A Tale of Two Stocks
- The Glitch in the Machine: Spotting AI-Generated Images Beyond the Obvious
- How to rank up with Tuvalkane – Soulframe
- Gold Rate Forecast
- 20 Best TV Shows Featuring All-White Casts You Should See
- TV Shows That Race-Bent Villains and Confused Everyone
2026-03-18 01:33